Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene, Pharmion deal

CELG will acquire PHRM for $72 per share, consisting of $25 in cash and the rest in CELG stock, for a total of $2.9 billion. The price is a 46%

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE